Inflammatory markers as exacerbation risk factors after asthma therapy switch from inhaled steroids to montelukast

Conclusions After switching treatment from a low-dose ICS, montelukast maintained control of asthma symptoms in 75% of patients. High sEos before the treatment change was the strongest exacerbation risk factor. In patients with asthma controlled by low-dose ICS and low inflammatory markers, treatment could be safely switched to montelukast.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research